Skip to content

A comparative study between Whitfields ointment + Oral fluconazole Vs 1% butenafine in tinea infections of skin

A comparative study to evaluate efficacy, safety and cost effectiveness between Whitfieldâ??s ointment + oral Fluconazole vs topical 1% Butenafine in tinea infections of skin - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/08/002914
Enrollment
120
Registered
2012-08-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Tinea infections of skin

Interventions

Intervention1: Whitfields Ointment + Oral Fluconazole vs 1% Butenafine: Whitfields ointment to be applied twice a day. Oral fluconazole (150 mg)to be taken once aweek for four weeks Control Interventi

Sponsors

Department of Pharmacology and Department of Skin and VD CU Shah Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: New patients attending skin O.P.D.

Exclusion criteria

Exclusion criteria: 1) Follow up cases 2) pregnant or lactating women, 3) patients having allergy to topical imidazole or any other antifungals used in the study

Design outcomes

Primary

MeasureTime frame
1. Change in baseline sign and symptoms score 2. Change in Physicianâ??s Global Evaluation Response b. Safety (No. of ADRs developed & percentage of the participants developing ADRs) c. Cost effectiveness (Incremental cost and Incremental effectiveness) Timepoint: one month

Secondary

MeasureTime frame
1. Assessment of clinico mycological correlation 2. Comparison of relapse rate with both the treatments 3. To identify and find the prevalence of different species of tinea Timepoint: one month

Countries

India

Contacts

Public ContactDr Saket J Thaker

NIL

drdimplesmehta@gmail.com09375060963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026